Remission Rates and Safety of Fecal Microbiota Transplantation in Inflammatory Bowel Disease in Adult Patients: A Systematic Review

To systematically evaluate clinical remission rates and safety profiles of FMT in IBD.Condition being studied Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a chronic gastrointestinal disorder that substantially impairs quality of life.Conventional therapies are often limited by suboptimal efficacy, adverse effects, and diminishing response over time.Fecal microbiota transplantation (FMT) has emerged as a therapeutic strategy aimed at restoring microbial balance, reducing inflammation, and improving outcomes. METHODS Search strategy Google Scholar; Scopus.Participant or population Adults with active inflammatory bowel disease (Crohn's disease or ulcerative colitis) who have received fecal microbiota transplantation.Intervention FMT via colonoscopy, alternative approaches (capsules, enemas, tubes), and comparative treatment. Comparator Conventional therapy, placebo, or no intervention.Study designs to be included Randomized controlled trials, controlled clinical trials, and observational studies.Eligibility criteria Studies were excluded if they involved pediatric populations, animal models, or non-peer-reviewed sources.Inclusion criteria were as follows:-Studies focusing on FMT in the management of IBD, including CD and UC.-Clinical trials (randomized controlled trials, controlled clinical trials, and observational studies) published after 2015.